Public Profile

Regeneron

Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.

DitchCarbon Score

How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

35

Industry Average

Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

24

Industry Benchmark

Regeneron's score of 35 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.

93%

Regeneron's reported carbon emissions

In 2023, Regeneron reported total carbon emissions of approximately 972,376,000 kg CO2e. This figure includes Scope 1 emissions of about 69,600,000 kg CO2e, Scope 2 emissions (market-based) of approximately 29,900,000 kg CO2e, and significant Scope 3 emissions totalling around 872,876,000 kg CO2e. The Scope 3 emissions are primarily driven by purchased goods and services, which account for about 660,589,000 kg CO2e. Regeneron has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The company has reported emissions data across all three scopes (1, 2, and 3) for the years 2019 through 2023, indicating a comprehensive approach to tracking and managing its environmental impact. Overall, Regeneron's emissions reflect its operations in the pharmaceutical industry, where addressing climate change is increasingly critical. The company continues to monitor its emissions and engage in sustainability practices, although further details on specific reduction strategies or targets are currently unavailable.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20162017201820192020202120222023
Scope 1
39,400,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
25,300,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
288,800,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Regeneron's primary industry is Research and development services (73), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Regeneron is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Regeneron is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Was this information valuable to you?

Similar Organizations

Genentech

US
Research and development services (73)
Updated 26 days ago

Bms

US
Chemicals nec
Updated 7 minutes ago

Sanofi

FR
Chemicals nec
Updated 17 minutes ago

MERCK Kommanditgesellschaft auf Aktien

DE
Research and development services (73)
Updated 4 days ago

Astra Zeneca

GB
Chemicals nec
Updated 4 days ago

Celanese

US
Chemicals nec
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers